ReviewAntiviral research2014
Antiviral strategies for hepatitis E virus.
Review in Antiviral research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- Triggering Degradation of Host Cellular Proteins for Robust Propagation of Influenza Viruses.International journal of molecular sciences · 2024Review
- Hepatitis E: Genotypes, strategies to prevent and manage, and the existing knowledge gaps.JGH open : an open access journal of gastroenterology and hepatology · 2021Review
- Immunological Manifestations of Hepatitis E-Associated Acute and Chronic Liver Failure and Its Regulatory Mechanisms.Frontiers in medicine · 2021Review
- Hepatitis E virus infection during pregnancy.Virology journal · 2020Review
- Clinical presentations of Hepatitis E: A clinical review with representative case histories.Clinics and research in hepatology and gastroenterology · 2019Review
- Antiviral Candidates for Treating Hepatitis E Virus Infection.Antimicrobial agents and chemotherapy · 2019Article
- Spicatoside A derived from Liriope platyphylla root ethanol extract inhibits hepatitis E virus genotype 3 replication in vitro.Scientific reports · 2019Article
- Mitochondrial electron transport chain complex III sustains hepatitis E virus replication and represents an antiviral target.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Potent Inhibition of Hepatitis E Virus Release by a Cyclic Peptide Inhibitor of the Interaction between Viral Open Reading Frame 3 Protein and Host Tumor Susceptibility Gene 101.Journal of virology · 2018Article
- Recent Advances Towards the Development of a Potent Antiviral Against the Hepatitis E Virus.Journal of clinical and translational hepatology · 2018Review
- In-silico design and molecular docking evaluation of peptides derivatives from bacteriocins and porcine beta defensin-2 as inhibitors of Hepatitis E virus capsid protein.Virusdisease · 2017Article
- Transcriptional Regulation of Antiviral Interferon-Stimulated Genes.Trends in microbiology · 2017Review
- A rat model for hepatitis E virus.Disease models & mechanisms · 2016Article
- Epidemiology of Hepatitis E in Pregnant Women and Children in Iran: A General Overview.Journal of clinical and translational hepatology · 2016Review
- Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication.Antimicrobial agents and chemotherapy · 2016Article
- Hepatitis E virus infection: Epidemiology and treatment implications.World journal of virology · 2015Review
- Hepatitis E: an old infection with new implications.Blood transfusion = Trasfusione del sangue · 2015Review
- Complete genome sequence of a rat hepatitis e virus strain isolated in the United States.Genome announcements · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hepatitis E virus is a common cause of acute hepatitis. Contrary to hepatitis B and C, hepatitis E is mostly a mild infection, although it has a high mortality in pregnant women and can evolve to chronicity in immunocompromised patients. Ribavirin and pegylated interferon-α are the only available therapies, but both have side effects that are not acceptable for prophylaxis or treatment of mild infections. In addition, these drugs cannot be used for all patient types (e.g. in case of pregnancy, specific organ transplants or co-morbidities) and in resource-poor settings. Hence there is an urgent need for better antiviral treatments that are efficacious and safe, also during pregnancy. In this review, a concise introduction to the virus and disease is provided, followed by a discussion of the available assay systems and potential molecular targets (viral proteins and host factors) for the development of inhibitors of HEV replication. Finally, directions for future research are presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.